Dexcom
Price data unavailable
Track DXCM in your trading journalAbout Dexcom
Dexcom (Nasdaq/NYSE: DXCM) is a Health Care Equipment company operating within the Health Care sector of the US equity market.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
The company reports trailing twelve-month revenue of $266.70M and net income of $199.50M.
Key metrics include a return on equity of 6.8%, a debt-to-equity ratio of 1.24.
Use FINOTAUR to track DXCM's price action, review fundamentals, and stay current with company news — all in one research dashboard.
Fundamentals
| Revenue (TTM) | $266.70M |
| Net Income (TTM) | $199.50M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | 6.75% |
| Debt-to-Equity | 1.24 |
| Dividend per Share | — |
Recent News
Want real-time analysis on DXCM?
Track it free in your trading journal. Log trades, tag setups, and review your edge.